Smith Matthew R
Massachusetts General Hospital, Boston, MA 02114, USA.
Cancer Treat Rev. 2006;32 Suppl 1:23-6. doi: 10.1016/s0305-7372(06)80006-x.
Although bone metastases from prostate cancer are described as osteoblastic, markers of both osteoblastic and osteoclastic activity are strikingly elevated in men with metastatic prostate cancer. Elevated markers of osteoblastic and osteoclastic activity are associated with adverse clinical outcomes in men with prostate cancer--outcomes including shorter time to skeletal complications, disease progression, and death. Bone marker measurement appears to be a promising method for monitoring the efficacy of bone-targeted therapy. Additional studies are needed to assess the potential role of bone markers in identifying men at highest risk for development of bone metastases.
尽管前列腺癌的骨转移被描述为成骨性的，但在转移性前列腺癌男性患者中，成骨细胞和破骨细胞活性的标志物均显著升高。成骨细胞和破骨细胞活性标志物升高与前列腺癌男性患者的不良临床结局相关，这些结局包括发生骨骼并发症、疾病进展和死亡的时间缩短。骨标志物检测似乎是监测骨靶向治疗疗效的一种有前景的方法。需要进一步研究来评估骨标志物在识别发生骨转移风险最高的男性患者方面的潜在作用。
